An autoantibody panel including those seven markers (CD99L2, RPL22, HCFC1R1, ANXA4, FXYD7, HDAC3, TP53) could add valuable information about the IPMN grade for approximately one third of patients, whereas the multinomial lasso model could not find a biomarker panel of reasonable power to distinguish between IPMN-HR and IPMN-LR. The gene discussed is ANXA4; the disease is pancreatic intraductal papillary-mucinous neoplasm.